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tion. Patients were divided into good responders (GR) or poor responders (PR) based
upon % change in LDL-C from baseline after initial statin dose.
Results: At baseline, PR had lower total cholesterol (TC) (227±35 vs 258±36 mg/
dl;p<0.001) and lower LDL-C (149±29 vs 173±28 mg/dl; p<0.001). Initial change in LDL-
C was -30.8±8.7% in GR vs. -8±7.2% in PR (p<0.01). Dose titration led to an additional
14.7±9.4% reduction in LDL-C in GR vs. only additional 7.7±11.6% in PR (p<0.001).
After dose titration, PR had less change from baseline in LDL-C (-15.7±14.6% vs -
45.5±12%; p<0.001). After dose titration, 18% of PR achieved LDL goal compared to
71% of GR (p<0.001). % LDL-C decrease after dose titration correlated with initial
response (r2=0.72).
Conclusions: Response to initial statin dose predicts response to dose titration. Dose
titration of statins is therefore not an effective strategy to reach aggressive LDL goals in
patients who have a poor initial LDL reduction. Other approaches such as combination
therapy need to be evaluated in this group of patients.
1084-172 Rosuvastatin Is Efficacious as Monotherapy in Patients 
With Combined Dyslipidemia
Fahim Abbasi, James W. Chu, Cindy Lamendola, Tracey McLaughlin, Valerie Cain, 
Howard G. Hutchinson, Gerald M. Reaven, Stanford University, Stanford, CA
Cardiovascular disease (CVD) risk is greater in patients with combined dyslipidemia
(CDL) than in those with isolated increases in fasting plasma triglyceride (TG) or low-
density lipoprotein (LDL) cholesterol (C) concentrations. Effective treatment (Rx) of CDL
has been confounded by: 1) concern of the increased risk of myopathy associated with
combined use of a “statin” and a fibric acid; and 2) neglecting the effect of Rx on post-
prandial (PP) lipemia. This study was initiated to test the hypothesis that the magnitude
of improvement in both fasting and PP lipid metabolism in rosuvastatin (RSV)-treated
subjects with CDL would obviate the need for combined drug Rx. Forty nondiabetic sub-
jects with CDL were randomly assigned to Rx with either RSV (40 mg/day) or gemfibrozil
(GEM, 1200 mg/day) for 3 months, and multiple aspects of fasting and PP carbohydrate
and lipid metabolism measured before and after Rx. The two groups did not differ in age,
sex distribution, or BMI. Mean±SE (mg/dL) fasting plasma LDL-C levels fell (P<0.001) fol-
lowing RSV-Rx (138±7 vs. 62±4), but did not change in GEM-treated subjects (126±5 vs.
131±5). Fasting TG levels fell (P<0.001), and to a similar degree in GEM-treated (284±17
vs. 166±23) and RSV-treated (324±19 vs. 211±18) subjects. RSV-treated subjects also
had significantly greater decreases in apo B-100, apo E, and the apo B-100/apo A-1 ratio
compared to those treated with GEM. Daylong glucose, insulin, and free fatty acid levels
did not change with Rx, whereas PP-TG levels fell to a similar degree in both groups
(P<0.01). Although the PP-remnant lipoprotein-C levels fell significantly with Rx in both
groups, the magnitude of the change was greater in the RSV-Rx group (P<0.05). Finally,
RSV-Rx resulted in significant (P<0.001) reductions in C-reactive protein (median change
-57.6%) compared to GEM-Rx (median change -9.1%). Conclusion: In addition to the
expected substantial decrease in LDL-C, the improvement in both fasting and PP con-
centrations of TG-rich lipoproteins in RSV-treated subjects was equal to or greater than
that seen with GEM-Rx. These results demonstrate that RSV provides effective mono-
therapy to decrease lipoprotein-related CVD risk factors in subjects with CDL.
1084-173 Analysis of the Renal Safety of Atorvastatin in a Broad 
Spectrum of Patients With Dyslipidemia
William Sasiela, Halit Silbershatz, Michael Szarek, Pfizer Inc, New York, NY
Background: This report summarizes the renal safety data from >9000 patients exposed
to atorvastatin for up to 2 years in completed clinical trials. These data are especially
important in the current climate which has seen increased scrutiny placed on all aspects
of the safety of chronic statin therapy.
Methods: Data were analyzed from 16,731 dyslipidemic patients (9976 male/6755
female; median age 61 yrs) enrolled in 44 clinical trials. The studies included 9416 atorv-
astatin-treated patients, 1789 placebo-treated patients and 5526 patients treated with
other statins (simvastatin [2771]; pravastatin [807]; lovastatin [968]; fluvastatin [744];
cerivastatin [236]). A broad spectrum of dyslipidemic patients with varying risks for car-
diovascular events were evaluated for up to 2 years. 
Results: Across the 44 studies analyzed, renal adverse events were rare in all 3 treat-
ment groups. Albuminuria was observed in 7 patients receiving atorvastatin (0.07%),
compared to 5 patients receiving other statins (0.09%) and 0 patients receiving placebo.
No case of albuminuria was considered to be treatment related. The rate of occurrence of
hematuria was also low in all treatment groups (atorvastatin, 44 patients [0.5%]; other
statins, 34 patients [0.6%]; placebo, 3 patients [0.2%]). Only in 1 atorvastatin and 1 pla-
cebo patient was hematuria considered to be possibly associated with study treatment.
In the subset of patients treated in placebo-controlled trials, there were no cases of albu-
minuria for either placebo or atorvastatin and hematuria was observed in 0.2% of
patients treated with placebo (3/1789) and in 0.3% of patients treated with atorvastatin
(8/2976). Overall, renal adverse events did not appear to be dose-related, and there were
no discontinuations considered related to renal adverse events.
Conclusion: Specific analysis of renal adverse events in 44 clinical trials demonstrates
that these occurred infrequently with atorvastatin and at similar rates to placebo. These
data provide further evidence to support the favorable clinical safety profile of atorvastatin
10 mg to 80 mg in a broad range of patients.
1084-174 Efficacy of Ezetimibe-10 mg/Day Coadministered With 
Multiple Doses of Simvastatin in Patients With Primary 
Hypercholesterolemia
Anne C. Goldberg, Rachel Capece, Aditi Sapre, Ji Liu, Yale Mitchel, Washington 
University, St. Louis, MO, Merck Research Laboratories, Rahway, NJ
Background: The cholesterol absorption inhibitor, ezetimibe (EZE), has a complemen-
tary mechanism of action to statins, which inhibit hepatic cholesterol synthesis. The pur-
pose of this study was to evaluate the LDL-C-lowering efficacy of EZE 10 mg/d
coadministered with simvastatin (SIM) 10, 20, 40, and 80 mg/d in hypercholesterolemic
patients (pts).
Methods: This was a 12 wk multicenter, double-blind, randomized, placebo (PBO)-con-
trolled study. After a 4-wk PBO/diet run-in, 887 pts with LDL-C 145 - 250 mg/dL and TG
<350 mg/dL were randomized to one of ten daily treatments: PBO; EZE 10 mg; SIM 10,
20, 40, or 80 mg; EZE 10 mg + SIM 10, 20, 40, or 80 mg.
Results: Results for LDL-C, non-high density lipoprotein cholesterol (non-HDL-C), trig-
lycerides (TG), and HDL-C by dose are summarized in the table. Pooled across the dose
ranges, EZE+SIM was more effective (p <0.001) than SIM in reducing LDL-C (-53.1% vs.
-38.3%), TG (-28.0% vs. -15.2%) and non-HDL-C (-48.5% vs. -34.1%), while HDL-C was
increased by 8% in both groups. A greater proportion of EZE+SIM pts reached the LDL-
C target of <100mg/dL (p <0.001): 82.4% (n=353) vs. 42.9% (n=345). Coadministration
of EZE+SIM was well tolerated and had an overall safety profile similar to that of SIM
monotherapy. However, there were more cases of consecutive >3 x upper limit of normal
elevations of aminotransferases in the EZE+SIM group vs. SIM group.
Conclusions: Overall, EZE+SIM was well tolerated and provided superior lipid-modify-
ing efficacy over SIM monotherapy.
1084-175 Changes in Coronary Plaque Color and Morphology by 
Lipid-Lowering Therapy With Atorvastatin: Serial 
Evaluation by Coronary Angioscopy
Masamichi Takano, Kyoichi Mizuno, Shigenobu Inami, Fumiyuki Ishibashi, Kentaro 
Okamatsu, Koji Seimiya, Takayoshi Ohba, Shinya Yokoyama, Shunta Sakai, Noritake 
Hata, Nippon Medical School, Chiba, Japan, Chiba-Hokusoh Hospital, Chiba, Japan
Background: The concept of coronary plaque stabilization by statin therapy has been
clarified. However, serial changes of coronary plaques by statin therapy in human have
not been examined in detail.
Methods: Thirty-one patients with coronary artery disease were devided into either the
comparison group (n=16) or the atorvastatin group (n=15). Before treatment and 12
months after, the color and complexity of 145 coronary plaques were determined accord-
ing to angioscopic findings. The yellow score of the plaque was defined as 0 (white), 1
(light yellow), 2 (yellow), or 3 (dark yellow), and its disrupted score was defined as 0
(smooth surface) or 1 (irregular surface) and as 0 (without thrombus) or 1 (with throm-
bus). In each patient, the mean yellow score and mean disrupted score were calculated.
Results: Mean low-density lipoprotein cholesterol (LDL-C) decreased by 45% in the ator-
vastatin group, whereas an increase of 9% was seen in the comparison group. The mean
yellow score decreased from 2.03 to 1.13 in the atorvastatin group, whereas it increased
from 1.67 to 1.99 in the comparison group. There was a good correlation between the
change in the mean yellow score and the change in LDL-C levels (r=0.81, p<0.0001).
The change in the mean yellow score and mean disrupted score differed significantly
between the two groups (p=0.002 and p=0.03, respectively).
Conclusions: This study indicated that lipid-lowering therapy changes plaque color and
morphology and should then lead to coronary plaque stabilization.
1084-176 Efficacy of Ezetimibe Coadminstered With Simvastatin 
Versus Atorvastatin in Patients With 
Hypercholesterolemia
Christie M. Ballantyne, Michael A. Blazing, Thomas R. King, William E. Brady, Joanne 
Palmisano, Merck & Company, Inc., West Point, PA
Background: This study was designed to evaluate the efficacy and safety of ezetimibe
coadministered with simvastatin (EZ/S) vs atorvastatin (A) in adults with hypercholester-
olemia.
Methods: After a four-week diet/placebo run-in period, eligible patients were randomized
1:1:1 to 3 treatment groups, each for four 6-week periods: (1) A10 mg titrated to A20 mg,
A40 mg, and A80 mg through Periods 1-4; (2) EZ/S 10 mg (10/10) titrated to EZ/S 20 mg
LDL-C response in GR vs. PR
Good Responders 
(n=38)
Poor Responders 
(n=38)
Change in LDL-C after initial 
dose
-30.8±8.7% -8.07.2%± p<0.001
Change in LDL-C after dose 
titration (from baseline)
-45.5±12% -15.7±14.6% p<0.001
% at  ATP III Goal 71% 18% p<0.001
Mean Percent Change from Baseline
Lipid 
Parameter
SIM 
10mg 
(n=79)
EZE/SIM 
10mg/10mg 
(n=87)
SIM 
20mg 
(n=89)
EZE/SIM 
10mg/20mg 
(n=86)
SIM 
40mg 
(n=90)
EZE/SIM 
10mg/40mg 
(n=89)
SIM 
80mg 
(n=87)
EZE/SIM 
10mg/80mg 
(n=91)
LDL
-C
-
31.
3
-
46.
2
-
34.
9
-
50.
5
-
41.
5
-
54.
9
-
45.
6
-
60.8
Total C -20.7 -31.5 -24.1 -36.5 -28.7 -39.5 -31.7 -43.0
non-
HDL-C
-26.8 -41.3 -31.2 -47.1 -37.0 -50.9 -41.4 -54.8
TG 
(median)
-4.5 -20.5 -13.6 -30.7 -18.6 -32.0 -25.7 -27.8
HDL-C 4.9 9.5 6.3 8.0 8.3 9.1 11.0 6.3
